Congress funds Lyme disease innovation race with $5M prize pot
H.R. 7482 — LymeX Authorization Act · Filed by Chris Smith (R-NJ) · 3 cosponsors · Introduced Feb 11, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the Secretary of Health and Human Services to spend up to $5 million on prize competitions designed to spur innovation in Lyme disease prevention, diagnosis, and treatment. The competitions would engage academia, nonprofits, businesses, and entrepreneurs to develop faster diagnostics and improve patient care.
Why we flagged it
The bill's operative mechanism is a straightforward appropriation to fund prize competitions under an existing statutory framework (Stevenson-Wydler Act). It is a targeted public-health measure with no hidden provisions or narrow carve-outs.
What the text implies
- Prize competitions may incentivize development of diagnostics or treatments that are profitable but not necessarily accessible to low-income or uninsured Lyme disease patients; public funding accelerates private innovation without guaranteeing affordability or equitable access.
- The bill does not specify IP ownership, licensing terms, or public-health safeguards; winning innovations could be patented and priced at market rates, limiting downstream public benefit.
- Success depends on HHS's administrative capacity to design, manage, and evaluate competitions; poor execution could waste appropriated funds with minimal innovation output.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Lyme disease affects hundreds of thousands of Americans annually; faster diagnostics and better treatments directly improve patient outcomes and reduce disease burden. Prize competitions are a cost-effective innovation mechanism that leverages private-sector expertise without direct government R&D overhead, and the $5M appropriation is modest and targeted to a genuine public health need.
Who stands to gain
- biotechnology and diagnostics companies
- pharmaceutical firms developing Lyme disease treatments
- academic research institutions
- small biotech startups and entrepreneurs
Named in the bill
Secretary of Health and Human Services, Stevenson-Wydler Technology Innovation Act of 1980, House Committee on Energy and Commerce, academia, nonprofits, small business, entrepreneurs
Where it stands
3 cosponsors: 3 Democrats.
- Feb 11, 2026 — Introduced · Congress.gov: “Introduced in House”
- Feb 11, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (834 characters) on Aug 17, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress funds Lyme disease innovation race with $5M prize pot” QuorumCivic. https://share.quorumcivic.app/bill/119/hr7482 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.